Core Viewpoint - The company has completed patient enrollment for the registration clinical study of its innovative temperature-sensitive embolic agent GPN00289 in China, marking a significant advancement in its research and development in the field of nuclear medicine for cancer treatment [1][3]. Group 1: Product Overview - GPN00289 is an innovative medical device recognized by the National Medical Products Administration of China, designed for treating hypervascular benign and malignant tumors. It features temperature-responsive properties that allow it to transition from liquid to solid state, enabling effective embolization of various blood vessels [2]. - The product exhibits good flowability at room temperature and can be delivered to the target blood vessels via microcatheters. Upon reaching body temperature, it solidifies in situ, achieving complete embolization of the target tissue's peripheral blood vessels, effectively preventing collateral circulation and ensuring long-lasting arterial blood flow blockage [2]. Group 2: Clinical Development and Strategic Plans - The global rights for GPN00289 are held by the company, which has entered the registration clinical study phase in China as of July 2024, with the first patient enrollment expected to be completed by December 2024. The company aims to actively promote the global registration and development of GPN00289 [3]. - The company plans to synergize GPN00289 with its existing product, Yttrium-90 microsphere injection, to enhance the treatment of liver cancer and deepen its industrial layout in the nuclear medicine oncology sector [3].
远大医药(00512.HK)全球创新温度敏感性栓塞剂在中国的注册性临床研究完成全部患者入组